oxi 4503 profile

Oxi 4503: diphosphate prodrug of cambretastatin A1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6918546
CHEMBL ID	1205402
SCHEMBL ID	12677563
MeSH ID	M0438341

Synonym
oxi-4503
ca1p
[3-methoxy-2-phosphonooxy-6-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate
CHEMBL1205402
oxi4503
oxi 4503
unii-jh6z94glud
jh6z94glud ,
combretastatin a1 diphosphate
1,2-benzenediol, 3-methoxy-6-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, 1,2-bis(dihydrogen phosphate)
combretastatin a-1 bis(phosphate)
288847-35-8
combretastatin a1 diphosphate [who-dd]
DB05143
SCHEMBL12677563
Q27095572
1,2-benzenediol,3-methoxy-6-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-,1,2-bis(dihydrogen phosphate)
1,2-benzenediol, 3-methoxy-6-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 1,2-bis(dihydrogen phosphate)
HY-16147
CS-0006163
combretastatin a1 phosphate
(z)-3-methoxy-6-(3,4,5-trimethoxystyryl)-1,2-phenylene bis(dihydrogen phosphate)

Excerpt	Reference	Relevance
"We have shown for the first time that PAI can observe the pharmacodynamic response of tumor vasculature to drug treatment both longitudinally and at different dose levels."	( Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors. Beard, P; Johnson, SP; Lythgoe, MF; Ogunlade, O; Pedley, RB, 2019)	0.51

Excerpt	Reference	Relevance
"This pre-clinical study was designed to investigate the effect of various vascular disrupting agents (VDAs) that have undergone or are in clinical evaluation, had on the oxygenation status of tumours and what effects that could have on the combination with radiation."	( Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. Busk, M; Horsman, MR; Iversen, AB, 2013)	0.39

Excerpt	Relevance	Reference
" In addition, the effects of continuous, daily and intermittent dosing (1-5 mg/kg) on tumor necrosis and growth were studied by quantitative histological and stereological analysis."	( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008)	0.35
" Subcutaneous continuous dosing infusion with Oxi4503 at 1 mg/kg/day reduced tumor growth compared to the controls, but was associated with marked systemic toxicity."	( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008)	0.35
" Intermittent dosing with Oxi4503 produced the maximum reduction in tumor growth, minimal toxicity, and a significant improvement in survival."	( Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. Chan, L; Christophi, C; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2008)	0.35

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (35.29)	29.6817
2010's	20 (58.82)	24.3611
2020's	2 (5.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (10.53%)	5.53%
Reviews	3 (7.89%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (81.58%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.11	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	4.09	2	0	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	3.64	1	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.13	1	0	pyrrole; secondary amine
evans blue Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.	2.04	1	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
nimorazole Nimorazole: An antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.	2.11	1	0	C-nitro compound; imidazoles
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	2.17	1	0	f-block element atom; lanthanoid atom
flavone acetic acid flavone acetic acid: structure given in first source	2.08	1	0
dimethylhydrazines Dimethylhydrazines: Hydrazines substituted with two methyl groups in any position.	2.04	1	0
carbogen carbogen: mixture of 95% O2 & 5% CO2	2.11	1	0
combretastatin combretastatin: cytotoxic principle from South African tree COMBRETUM caffrum; structure given in first source; acts at COLCHICINE site of TUBULIN	4.61	4	0
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	4.35	3	0	monocarboxylic acid; xanthones	antineoplastic agent
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	11.14	34	4	stilbene
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	11.14	34	4	diphosphate ion
su 11248 [no description available]	2.13	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
fosbretabulin fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source	6.94	8	1
nsc 600032 combretastatin A-1: from Combretum caffrum; structure given in first source	3.89	2	1
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	2.03	1	0	carbon group element atom; metalloid atom; nonmetal atom
soblidotin soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R(R),2S),2R(1S,2S)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.	3.15	1	0	tetrapeptide	antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
ac 7700 AC 7700: a vascular disrupting agent; structure in first source	4.09	2	0
zd 6126 [no description available]	4.69	3	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.07	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Angiogenesis, Pathologic [description not available]	0	8.09	12	1
Colorectal Cancer [description not available]	0	4.61	9	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	4.61	9	0
Bleeding [description not available]	0	3.64	1	1
Dysmyelopoietic Syndromes [description not available]	0	3.64	1	1
Acute Respiratory Distress Syndrome [description not available]	0	3.64	1	1
Acute Myelogenous Leukemia [description not available]	0	3.9	2	1
Hemorrhage Bleeding or escape of blood from a vessel.	0	3.64	1	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	1	5.64	1	1
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	0	3.64	1	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1	5.9	2	1
Disease Exacerbation [description not available]	0	2.25	1	0
Animal Mammary Carcinoma [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.76	3	0
Glial Cell Tumors [description not available]	0	2.17	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	0	2.17	1	0
Anoxemia [description not available]	0	3.36	2	0
Experimental Mammary Neoplasms [description not available]	0	3.17	5	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	3.36	2	0
Cancer of Gastrointestinal Tract [description not available]	0	3.01	1	0
Minimal Disease, Residual [description not available]	0	2.08	1	0
Cancer of Liver [description not available]	0	3.18	5	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	3.18	5	0
Benign Neoplasms [description not available]	0	7.91	6	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	9.91	6	3
Metastase [description not available]	0	2.11	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.11	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.13	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.13	1	0
Bone Cancer [description not available]	0	2.05	1	0
Ewing Sarcoma [description not available]	0	2.05	1	0
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	0	2.05	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	5.25	7	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	0	2.05	1	0
Malignant Melanoma [description not available]	0	3.43	1	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	3.43	1	1
Adenocarcinoma Of Kidney [description not available]	0	2.44	2	0
Cancer of Kidney [description not available]	0	2.44	2	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	0	2.44	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	2.44	2	0
Chloroma [description not available]	0	2.05	1	0
Sarcoma, Myeloid An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.	0	2.05	1	0
EHS Tumor [description not available]	0	2.45	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.47	2	0
Leucocythaemia [description not available]	0	2.07	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	2.07	1	0
Endothelioma, Vascular [description not available]	0	2.02	1	0
Hemangioendothelioma A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)	0	2.02	1	0
Experimental Neoplasms [description not available]	0	2.94	1	0
Experimental Hepatoma [description not available]	0	2.04	1	0

oxi 4503

Description

Cross-References

Synonyms (22)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (34)

Market Indicators

Research Demand Index: 18.44

Study Types

oxi 4503

Description

Cross-References

Synonyms (22)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (34)

Market Indicators

Research Demand Index: 18.44

Study Types

Related Drugs (22)

Related Conditions (50)